Multiple updates in this batch point to a high-stakes portfolio recalibration across biotech. GSK’s $750 million bet on Chimagen’s tri-specific T-cell engager adds to the company’s immuno-oncology push, while other assets show how quickly pipelines can re-rate after setbacks. On the operational side, Sionna announced a 46% workforce reduction after an unexpected cystic fibrosis trial failure, illustrating how clinical outcomes directly translate into cost and runway decisions. Taken together, these moves show investors are rewarding clean clinical readouts and penalizing execution risk, with companies tightening budgets and accelerating decisions on which programs get continued capital.